

**Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice**

# Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

# Expert panel



**Prof. Nikhil Munshi**

Dana-Farber Cancer Institute  
Boston, MA, USA



**Prof. Sarah Holstein**

University of Nebraska Medical Center  
Omaha, NE, USA



**Prof. Noopur Raje**

Harvard Medical School  
Boston, MA, USA




# Agenda

**Navigating treatment decisions in patients with RRMM who have relapsed following 1–3 prior lines of therapy**

**Addressing the complexities of treatment choice in heavily pretreated patients with RRMM following >3 prior lines of therapy**

**Unravelling sequencing strategies for patients with RRMM in the early- and later-line settings**



# Navigating treatment decisions in patients with RRMM who have relapsed following 1–3 prior lines of therapy

**Prof. Nikhil Munshi**

Dana-Farber Cancer Institute  
Boston, MA, USA



# Selected phase III trials in RRMM: ≤3 lines of therapy

Trial	Regimen (ratio)	mFU, mo	ORR, %	mPFS, mo	OS, mo
ELOQUENT-2 (N=635) <sup>1,2</sup>	<b>Elo-Rd</b> vs Rd (1:1)	48	79 vs 66	19 vs 15	48 vs 40 <sup>*</sup>
APOLLO (N=304) <sup>3</sup>	<b>Dara-Pd</b> vs Pd (1:1)	17	69 vs 46	12 vs 7	—
CASTOR (N=498) <sup>4,5</sup>	<b>Dara-Vd</b> vs Vd (1:1)	19	85 vs 63	17 vs 7	50 vs 39 <sup>†</sup>
CANDOR (N=466) <sup>6,7</sup>	<b>Dara-Kd</b> vs Kd (2:1)	≈27	84 vs 75	29 vs 15	NR vs NR
ICARIA-MM (N=307) <sup>8,9</sup>	<b>Isa-Pd</b> vs Pd (1:1)	12	60 vs 35	12 vs 7	25 vs 18 <sup>‡</sup>
IKEMA (N=302) <sup>10,11</sup>	<b>Isa-Kd</b> vs Kd (3:2)	44	87 vs 84	36 vs 19	—
OPTIMISSM (N=559) <sup>12</sup>	<b>PVd</b> vs Vd (1:1)	16	82 vs 50	11 vs 7	—
BOSTON (N=402) <sup>13</sup>	<b>SVd</b> vs Vd (1:1)	13 vs 17	76 vs 62	14 vs 9	NR vs 25 <sup>§</sup>

Treatment for patients with RRMM varies, as some patients have received prior stem cell transplants which dictates up-front drug regimen selection, in particular the timing and dosing of R.

Specific data from clinical trials on patients refractory to R are lacking to guide critical clinical decisions for these patients<sup>14</sup>

Direct comparisons between trials should not be made due to differences in trial design.

\*Minimum follow-up = 70.6 mo; †median follow-up = 72.6 mo; ‡median follow-up = 35.3 mo; §median follow-up = 17.3 mo (Svd) vs 17.5 mo (Vd).

d, dexamethasone; dara, daratumumab; elo, elotuzumab; FU, follow-up; isa, isatuximab; K, carfilzomib; m, median; mo, months; NR, not reached; ORR, overall response rate; OS, overall survival; P, pomalidomide; PFS, progression-free survival; R, lenalidomide; RRMM, relapsed or refractory multiple myeloma; S, selinexor; V, bortezomib.

1. Dimopoulos MA, et al. *Cancer*. 2018;124:4032–43; 2. Dimopoulos MA, et al. *Blood Cancer J*. 2020;10:91; 3. Dimopoulos MA, et al. *Lancet Oncol*. 2021;22:801–12; 4. Sonneveld P, et al. *J Clin Oncol*. 2023;41:1600–9; 5. Mateos M-V, et al. *Clin Lymphoma Myeloma Leuk*. 2020;20:509–18; 6. Usmani SZ, et al. *Lancet Oncol*. 2022;23:65–76; 7. Dimopoulos MA, et al. *Lancet*. 2020;396:186–97;

8. Richardson PG, et al. *Lancet Oncol*. 2022;23:416–27; 9. Attal M, et al. *Lancet*. 2019;394:2096–107; 10. Moreau P, et al. *Lancet*. 2021;397:2361–71; 11. Moreau P, et al. *Ann Oncol*. 2022;33:664–5;

12. Richardson PG, et al. *Lancet Oncol*. 2019;20:781–94; 13. Grosicki S, et al. *Lancet*. 2020;396:1563–73; 14. Raju N, et al. *Blood Cancer J*. 2023;13:41.

# Factors influencing treatment sequencing in patients with RRMM<sup>1,2</sup>



## Disease characteristics

- Genetic alterations
  - Cytogenic risk
- Duration of prior remission
- Extramedullary disease
- Tumour burden
- Rate of increase of M-protein
- End-organ function

## Patient characteristics

- Age and frailty
- Performance status
- Comorbidities\*
- Bone marrow reserve
- Patient preference
- Clinical trial eligibility
- Treatment compliance/access

## Prior therapy

- Prior therapy and refractoriness
  - IMiD
  - PI
  - anti-CD38 mAb
- Response observed
- Toxicities experienced
- SCT
  - Eligibility
  - Prior SCT

Treatment goals vary among patients with RRMM. Disease control, extension of survival and maintenance of QoL are important considerations when setting treatment goals<sup>1</sup>

\*For example, CVD, COPD, renal impairment and polyneuropathy.

CD, cluster of differentiation; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; IMiD, immunomodulatory drug; mAb, monoclonal antibody; PI, proteasome inhibitor; QoL, quality of life; RRMM, relapsed or refractory multiple myeloma; SCT, stem cell transplant.

1. Podar K, Leleu X. *Cancers (Basel)*. 2021;13:5154; 2. van de Donk, NWCJ. *Hematology Am Soc Hematol Educ Program*. 2020;2020:248–58.

# Patient with RRMM, case 1: Younger, R-refractory



Male, 54 years



## Patient and disease characteristics

- No comorbidities
- Performance status: 0
- Bone marrow: 50% with t(11;14)

## Prior therapy

- Treated initially with RVd and auto-SCT
  - R-maintenance

## Current situation

- Disease has progressed after 3 years

What should the patient be offered next?



# Patient with RRMM, case 2: Older, non-R-refractory



Female, 78 years



## Patient and disease characteristics


- Hypertension and evidence of renal insufficiency
- Performance status: 1
- Bone marrow: 60% with t(4;14)

## Prior therapy

- Auto-SCT ineligible; treated initially with VCd
  - Progression: 8 months
- Second line: Dara-Rd
  - Progression: 10 months


What should the patient be offered next?

# Selected treatment options following early relapse<sup>1-3</sup>



\*After two prior therapies including R and a PI; †after two prior therapies including an IMiD and a PI and disease progression on/within 60 days of completion of last therapy.  
 C, cyclophosphamide; d, dexamethasone; dara, daratumumab; elo, elotuzumab; i, ixazomib; IMiD, immunomodulatory drug; isa, isatuximab; K, carfilzomib; P, pomalidomide; PI, proteasome inhibitor; R, lenalidomide; S, selinexor; V, bortezomib.

1. NCCN. Clinical Practice Guidelines in Oncology: Multiple myeloma. Version 3. 2023. Available at: [www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf) (accessed 10 May 2023);  
 2. Podar K, Leleu X. *Cancers (Basel)*. 2021;13:5154; 3. van de Donk NWCJ. *Hematology Am Soc Hematol Educ Program*. 2020;2020:248-58.



# Addressing the complexities of treatment choice in heavily pretreated patients with RRMM following >3 prior lines of therapy

**Prof. Nikhil Munshi**

Dana-Farber Cancer Institute  
Boston, MA, USA



# Selected recommendations for patients treated with >3 prior lines of therapy<sup>1\*</sup>

## >3 lines of therapy

- Earlier line combinations that have not been used previously, including P, K, Isa and S
- High dose/fractionated C
- Bendamustine +/- Vd **or** Kd **or** Rd

## >4 lines of therapy including, an anti-CD38 mAb, a PI and an IMiD

- Idecabtagene vicleucel
- Ciltacabtagene autoleucel
- Teclistamab
  - Belantamab mafodotin-blmf<sup>†</sup>


Patients with RRMM in later lines may be triple or quadruple refractory; in still later relapses they may also be penta-exposed, or even penta-refractory<sup>2</sup>

\*Selected regimens. Regimens are ordered according to NCCN category of evidence and consensus alphabetically; <sup>†</sup>useful in certain circumstances if available through the compassionate use programme. C, cyclophosphamide; CAR, chimeric antigen receptor; CD, cluster of differentiation; d, dexamethasone; IMiD, immunomodulatory drug; Isa, isatuximab; K, carfilzomib; mAb, monoclonal antibody; P, pomalidomide; PI, proteasome inhibitor; R, lenalidomide; RRMM, relapsed or refractory multiple myeloma; S, selinexor; V, bortezomib.

1. NCCN. Clinical Practice Guidelines in Oncology: Multiple myeloma. Version 3.2023. Available at: [www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf) (accessed 10 May 2023);

2. Nathwani N, et al. *Am Soc Clin Oncol Educ Book*. 2021;41:358-75.

# Patient with RRMM, case 1: Younger, R-refractory



What should the patient be offered next?

# Patient with RRMM, case 2: Older, non-R-refractory



Female, 78 years



81 years



## Patient and disease characteristics

- Hypertension and evidence of renal insufficiency
- Performance status: 1
- Bone marrow: 60% with t(4;14)

## Prior therapy

- Auto-SCT ineligible; treated initially with VCd
  - Progression: 8 months
- Second line: Dara-Rd
  - Progression: 10 months



## Patient and disease characteristics

- History of coronary heart disease (EF: 50%)
- Performance status: 2

## Prior therapy

- Third line: KPd
  - Progression: 2 months
- Fourth line: KCd
  - Progression: 2 months

What should the patient be offered next?

# Unravelling sequencing strategies for patients with RRMM in the early- and later-line settings

**Prof. Nikhil Munshi**

Dana-Farber Cancer Institute  
Boston, MA, USA



# Emerging therapeutic strategies for RRMM



## ADC<sup>1</sup>

- Anti-BCMA + amanitin derivative
- Modakafusp alpha\*



## BsAb

### Targets

- BCMA-CD3<sup>1</sup>
- BCMA-CD38<sup>1</sup>
- GPRC5D-CD3<sup>2</sup>
- FcRH5-CD3<sup>2</sup>



## CAR T-cell therapies<sup>1,2</sup>

### Targets

- Anti-BCMA allo-CAR T
- GPRC5D CAR T



## IMiD – CELMoDs<sup>3</sup>

- Iberdomide
- Mezigdomide



## Novel small molecules

- **Anti-BCL-2:** BGB-11417<sup>4</sup>
- **Anti-GLS1:** Telaglenastat<sup>5</sup>
- **Anti-HDAC class I and IIb:** Purinostat mesylate<sup>6</sup>

New therapeutic options for patients with RRMM in the later line include ADCs, BsAbs and CAR T cells; trials are currently underway to translate approved CAR T cells into the earlier line setting<sup>3</sup>

\*Immunocytokine.

ADC, antibody-drug conjugate; allo, allogenic; BCL-2, B-cell leukaemia/lymphoma-2; BCMA, B-cell maturation antigen; BsAb, bispecific antibody; CAR, chimeric antigen receptor; CD, cluster of differentiation; CELMoD, cereblon E3 ligase modulating drug; FcRH5, Fc receptor-homolog 5; GLS, glutaminase; GPRC5D, G protein-coupled receptor, class C, group 5; HDAC, histone deacetylase; IL, interleukin; IMiD, immunomodulatory drug; RRMM, relapsed or refractory multiple myeloma.

1. Shah N, et al. *Leukemia*. 2020;34:985–1005; 2. Podar K, Leleu X. *Cancers (Basel)*. 2021;13:5154; 3. Raje N, et al. *Blood Cancer J*. 2023;13:41; 4. Quach H, et al. *Blood*. 2022;140(Suppl. 1):7269–71; 5. Gonsalves WI, et al. *Blood*. 2022;140(Suppl. 1):7315–6; 6. Wang J, et al. *Blood*. 2022;140(Suppl. 1):6612–3.



# Patient with RRMM, case 1: Younger, R-refractory

